External Evaluation of Vancomycin Population Pharmacokinetic Models
NCT ID: NCT05481788
Last Updated: 2022-08-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
300 participants
OBSERVATIONAL
2021-04-16
2021-11-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Seven pharmacokinetic models' predictive performance will be evaluated on this database.
Using the best model, we will perform Monte-Carlo simulation to elaborate dosing nomograms and develop dosing recommandations of continuous infusion of vancomycin.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Model-informed Precision Dosing of Vancomycin in Adults
NCT05535075
Evaluation of the Dosing Regimen of Vancomycin in Pediatric Patients
NCT03560440
Pharmacokinetics of Vancomycin in Adults Receiving ECMO
NCT00281281
Vancomycin Dose Adjustments Comparing Trough Levels to The AUC/MIC Method Using a Bayesian Approach in a Hospitalized Adult Population
NCT04756895
Vancomycin Dose Optimization in Obesity
NCT06601257
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* treated with vancomycin and receiving pharmacological monitoring
* between 1rst January 2019 and 1rst January 2021
Exclusion Criteria
* Refusal to be included in this study
* Hospitalisation in ICU
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Brest
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Brest University Hospital
Brest, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EOPMV - 29BRC21.0126
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.